Notice: Undefined index: User-Agent in /var/www/html/wp-config.php on line 121
Seeking biotech assets leveraging immuno-oncology

Seeking biotech assets and platform technologies leveraging immuno-oncology to treat solid tumour cancers

Submit your assets and have them sent to and reviewed by R&D decision-makers in biopharma companies across our global industry network with active immuno-oncology pipelines.

Through this Global Challenge campaign, which is open to submissions from the 31st of January 2023 to the 14th of March 2023, we invite biotechnology companies to share with us non-confidential details of out-licensing opportunities targeting solid tumour cancers by harnessing the immune system. 

This is the first time we have opened up our Global Challenge programme to submissions from biotech companies. Historically we have worked to surface academic research and assets to partner with industry. But now, through our integration with Inova, we are opening up our partnering platforms for biotech companies to engage directly with potential biopharma partners. 

Three industry partners who are actively looking to leverage immuno-oncology innovations to treat cancer – MSD, Tocris Bioscience, and Immunitas Therapeutics – are partners on this campaign to ensure a clear pathway to market for new innovations in the space. R&D leads at each of these companies have shared their R&D priorities and partnering requirements through one-page interest documents (links below) and each of them will be presenting them in more detail through a series of online ‘industry partnering events’ (register for these here).

The ultimate aim of this campaign is to start valuable new conversations between teams across industry and academia to support the development and deployment of new, improved and more effective immuno-oncology interventions that ensure greater quality of life for cancer patients across the globe. 

If you have any questions or want to better understand how you can get involved, share your queries to submissions@in-part.co.uk and a member of our Global Challenge team will get back to you promptly.

How does the campaign work?

Submitting your assets and out-licensing opportunities to the campaign and having them disseminated to pharmaceutical companies in our network is free and doesn’t require a subscription to IN-PART.

Our role in the research ecosystem is to simplify the initial connection between relevant partners across industry and academia based on the alignment of research interests. We do the matching, set up the conversations, and then leave the partners to explore and establish collaborations. We don’t take any success fees from successful partnerships from campaigns or through our platforms.

Submissions to the campaign will be disseminated to industry teams with aligned interests from March 2023 onwards and, based on their performance, will feature in our post-campaign content programme and research trends white paper.

The campaign is open to submissions from Tuesday 31st January 2023, and the deadline for submissions is Tuesday 14th March 2023.

Who should respond to the campaign?

We want to hear from any biotech companies that are developing immuno-oncology assets that can be developed with an industry partner to treat or facilitate the treatment of solid tumours in cancer patients. 

These campaigns help us to raise our profile and to grow our academia-industry networks (into which there is a free entry point for every stakeholder), but our core ambition is to contribute to the research ecosystem and society by leveraging our position between the two worlds and our experience in bringing them together. 

What assets should you submit?

This campaign has been informed by leading companies and industry stakeholders whose work focuses on the relationship between the immune system and solid tumour cancers. The R&D and external innovation priorities of each of our industry partners can be found through the following links:

The scope of the opportunities we’re seeking as part of this campaign include, but are not limited to; therapeutics such as immune checkpoint inhibitors; CAR-T therapy; monoclonal antibodies; cancer vaccines; and technologies targetting or transferable to the tumour microenvironment.

A full breakdown of the most pressing research topics we’ve identified to be of priority can be found in the submission form.

In addition to our campaign partners, we also have an extended network of 2,000+ pharmaceutical and biotech companies with active pipelines in the immuno-oncology space. We will be disseminating the campaign submissions to industry teams across this network whose interests cover every angle of solid tumour immunotherapy R&D. 

How to submit your assets and out-licensing opportunities:

Provide a short (300-500 words) non-confidential summary of your assets, platform technologies, or out-licensing opportunities using the submission form and submit it by email to submissions@in-part.co.uk (there will be no costs from IN-PART to engage with this campaign at any stage).

How to find new opportunities for your pipeline:

If you are also looking to identify new assets and partnering opportunities to drive your R&D pipeline, you can view the academic submissions and the biotech submissions to the campaign through the following links

And if you’d like us to dissemination your in-licensing requirements to our academic network (which has embedded relationships in over 2,600 universities and research institutes worldwide), outline your search needs through the following form and our Global Challenges team will send you a curated list of the most relevant opportunities we surface. 

 

Other important details:

  • Information about your assets will be distributed to industry R&D teams with aligned research interests through our online matchmaking platform, Connect.
  • Submitting your work does not require a subscription to our platform, there will be no costs from IN-PART at any stage to engage with this campaign.
  • Support from our team of STEM experts will be provided where required to review and quality-control submissions.
  • Any information sent to us should be non-confidential.
  • A maximum of 6 submissions can be made per person and we reserve the right to only accept assets that are aligned with the aims and themes outlined in the call. 
  • We strongly recommend submitting your assets in advance of the campaign deadline to maximise exposure with our industry networks.

 

Campaign partners

This campaign is being run with support from:

Labiotech.eu is the leading digital media covering the global biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Learn more.

ASTP are Europe’s premier association of knowledge transfer professionals whose work aims to improve the quality of impact that public research has on the economy and society. Learn more.

PraxisAuril are a world-leading professional association for knowledge exchange practitioners, whose network includes 5000+ KE professionals. Learn more.

BioIndustry Association (BIA) is the voice of the life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. Learn more.

Written by Alex Stockham. Edited by Robin Knight.

Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2023: ‘Seeking novel academic research and assets in immuno-oncology to treat solid tumour cancers’

IN-PART:

We believe brilliant connections can solve real-world problems. We match research pioneers from academia with decision-makers in industry sectors striving for a greater positive impact.

Our goal is to enable connections from around the world to match academic research with industry on a level playing field. Through our intelligent, matchmaking platform we showcase leading university innovations and connect academics with an international community of decision-makers in industry, creating meaningful dialogue and partnership.

Connect, a digital partnering platform for university-industry collaboration.

250+ universities and research institutes around the world currently showcase their research and innovation on IN-PART to find new collaboration partners in industry. R&D teams get free access to the platform (create an account here). There are no hidden costs and we don’t claim downstream success fees.

Discover, a bespoke scouting service for open innovation.

Through Discover, corporate R&D teams can leverage our extended academic network, which reaches multiple teams across 2,600+ universities and research institutes worldwide. In response to a specific research requirement or challenge, Discover enables R&D teams to identify new opportunities for commercialisation or to solicit proposals for new research.

Interested in speaking with our Discover team? Request a demo |  TTO or academic? Sign-up for weekly Discover emails.